Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces that it has entered into a binding term sheet to be acquired by Kuva Labs, Inc. (“Kuva”), a privately-held company. In November 2024, Kuva had licensed Lisata’s iRGD cyclic peptide product candidate, certepetide, as a targeting and enhanced delivery agent to be used with Kuva’s NanoMark™ platform technology and has begun development of a potentially new class of advanced magnetic resonance (MR) imaging agents that could enable the safe, non-invasive and unambiguous detection of solid tumor cancers.
Read the full article: Lisata Therapeutics Enters into Term Sheet to Be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer //
Source: https://www.globenewswire.com/news-release/2026/01/21/3222654/18623/en/Lisata-Therapeutics-Enters-Into-Term-Sheet-to-be-Acquired-by-Kuva-Labs-for-4-00-Per-Share-in-an-All-Cash-Tender-Offer.html